Magazine article Drug Topics

Will Clarinex Take over the Mantle of Claritin?

Magazine article Drug Topics

Will Clarinex Take over the Mantle of Claritin?

Article excerpt

Many people will probably see Schering-Plough's newest product, Clarinex (desloratadine), as an attempt to extend the loratadine (Claritin raw train. After all, the first patent on loratadine expires in December of this year, and the company plans to launch desloratadine, another nonsedating antihistamine, this month.

Desloratadine is an active metabolite of loratadine. According to package inserts, the two drugs are quite similar, as would be expected. Both are indicated for treatment of seasonal allergic rhinitis symptoms (both nasal and non-nasal), although loratadine is approved for patients as young as two years. Desloratadine is indicated for patients 12 years and older.

Schering has already received an approvable letter for chronic idiopathic urticaria for desloratadine, an indication approved for loratadine, and Food & Drug Administration response is pending on an allergic rhinitis indication.

Although Schering could argue that the new drug is a more purified form of loratadine, the company prefers not to compare the two products. According to William O'Donnell, a spokesman for Schering, desloratadine "is a new chemical entity." He also said the drug relieves both nasal and nonnasal symptoms consistently and effectively for 24 hours. "It helps address concerns that currently available medications don't relieve."

Pharmacists and third parties, however, will likely be closely comparing the two drugs. Both loratadine and desloratadine are selective Hl antagonists and are more effective than placebo at relieving allergy symptoms. Unlike loratadine, desloratadine absorption is not dramatically increased by food. Desloratadine levels-and those of its major active metabolite, 3-hydroxydesloratadinewere increased by cytochrome P-450 inhibitors, but not to the same extent that loratadine levels were.

A curious occurrence with desloratadine is that about 7% of study subjects were "slow metabolizers" of the drug, according to the labeling. While the half-life in most patients was 27 hours, in these patients the half-life was 50 hours or more. The slow metabolizers were exposed to six times more loratadine than the other study subjects. One would expect more side effects as a result, but this was not proven in the pharmacokinetic studies.

In clinical trials of desloratadine, frequency of side effects was quite low, even lower than reported in loratadine trials, and no serious adverse events occurred. The study results did not identify or separate slow metabolizers from the rest of the population, so it is uncertain just how many of those experiencing side effects were in this group. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.